Amycretin
Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.[1][2][3][4][5]
Initial trials[edit]
On 7 March 2024, Novo Nordisk announced the results from the Phase I trial of the pill form of Amycretin showed participants lost 13.1% of their weight after 12 weeks. For comparison, clinical trials for the older drug Wegovy which was also developed by Novo Nordisk indicated weight loss of 6% after 12 weeks and 15% after 68 weeks.[6]
Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecasts the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.[6]
References[edit]
- ^ Melson, Eka; Ashraf, Uzma; Papamargaritis, Dimitris; Davies, Melanie J. (1 February 2024). "What is the pipeline for future medications for obesity?". International Journal of Obesity: 1–19. doi:10.1038/s41366-024-01473-y. ISSN 1476-5497.
- ^ Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug". MarketWatch. Retrieved 11 March 2024.
- ^ Jamaluddin, Aqfan; Gorvin, Caroline M (21 March 2023). "RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis". Journal of Molecular Endocrinology. 70 (4). Bioscientifica. doi:10.1530/jme-23-0014. ISSN 0952-5041. PMC 10160555.
- ^ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663. ISSN 1467-7881.
- ^ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (March 2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663.
- ^ a b ""Novo valuation surpasses Tesla on experimental obesity drug data"". Reuters. 7 March 2024. Retrieved 13 March 2024.